|
🐜
|
Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study.
9 auth.
T. V. van Himbergen,
A. Beiser,
M. Ai,
S. Seshadri,
S. Otokozawa,
R. Au,
...
N. Thongtang,
P. Wolf,
E. Schaefer
|
7 |
2012 |
7
🐜
|
|
🦁
|
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
9 auth.
N. Thongtang,
M. Ai,
S. Otokozawa,
T. V. Himbergen,
B. Asztalos,
K. Nakajima,
...
E. Stein,
Peter H. Jones,
E. Schaefer
|
6 |
2011 |
6
🦁
|
|
🦁
|
Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin1[S]
8 auth.
N. Thongtang,
M. Diffenderfer,
E. Ooi,
P. Barrett,
Scott M. Turner,
N. Le,
...
W. Brown,
Ernst J. Schaefer
|
5 |
2017 |
5
🦁
|
|
🐜
|
Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East
11 auth.
Mostafa Q Alshamiri,
M. Ghanaim,
P. Barter,
Kuan-Cheng Chang,
Jian‐Jun Li,
B. Matawaran,
...
A. Santoso,
S. Shaheen,
K. Suastika,
N. Thongtang,
Ahmad KM Yusof
|
5 |
2018 |
5
🐜
|
|
🦁
|
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.
7 auth.
N. Thongtang,
Jianxin Lin,
E. Schaefer,
R. Lowe,
J. Tomassini,
Arvind K. Shah,
...
A. Tershakovec
|
5 |
2012 |
5
🦁
|
|
🦁
|
Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices
N. Thongtang,
R. Sukmawan,
E. Llanes,
Zhen-Vin Lee
|
5 |
2022 |
5
🦁
|
|
🐬
|
Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region
Zhen-Vin Lee,
E. Llanes,
R. Sukmawan,
N. Thongtang,
H. T. Ho,
P. Barter
|
4 |
2021 |
4
🐬
|
|
🐢
|
Coexistence of Graves’ disease and unilateral functioning Struma ovarii: a case report
T. Sitasuwan,
S. Hanamornroongruang,
T. Peerapatdit,
N. Thongtang
|
3 |
2015 |
3
🐢
|
